<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510078</url>
  </required_header>
  <id_info>
    <org_study_id>0695-17-RMC</org_study_id>
    <nct_id>NCT03510078</nct_id>
  </id_info>
  <brief_title>Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients</brief_title>
  <official_title>Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperglycemia is a common condition among hospitalized patients. The occurrence of severe&#xD;
      hyperglycemia is associated with increased morbidity and mortality in several populations.&#xD;
      Several trials assessed the benefits of aggressive versus conventional glucose control. These&#xD;
      studies evaluated different patient populations, glucose targets and treatment protocols and&#xD;
      as a result reported conflicting results. To date there are no clear guidelines regarding to&#xD;
      the preferred glucose target range in hospitalized non-critically ill patients. The common&#xD;
      practice is to maintain glucose level lower than 180 mg/dl however there are no evidence&#xD;
      based regarding to the outcomes of hospitalized patients treated with intensive compared to&#xD;
      conventional glycemic control. This prospective randomized controlled study will compare&#xD;
      intensive vs. standard glycemic control in hospitalized non-critically ill patients.&#xD;
&#xD;
      Within 24 hours of hospitalization in the internal medical or geriatric departments, patients&#xD;
      who are expected to require hospitalization for at least three consecutive days will be&#xD;
      randomly assigned into one of the two study groups - intensive with a target blood glucose&#xD;
      range of 130 mg per deciliter or less, or conventional glucose control, with a target of&#xD;
      130-180 mg per deciliter. The investigators defined the primary end point as a composite&#xD;
      outcome of mortality in 30 days, severe hypoglycemia, severe infections within 30 days, CVA&#xD;
      and cardiac ischemic events within 30 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of: 1. mortality in 30 days</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe hypoglycemia</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe infections</measure>
    <time_frame>30 days</time_frame>
    <description>Severe infections will be defined as a hospitalization as a result of sepsis, pneumonia or soft tissue infection or other infection requiring intravenous antibiotic therapy that occurred during hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebro-Vascular accidents</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac ischemic events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each component of the primary outcomes</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat hospitalizations within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Repeated hospitalizations will be defined as the number of repeated hospitalizations in 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe infections within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Severe infections will be defined as a hospitalization as a result of sepsis, pneumonia or soft tissue infection or other infection requiring intravenous antibiotic therapy that occurred during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>90 days</time_frame>
    <description>Will be measured as the number of days from the admission to the discharge from hospital.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Non-critically Ill Patients</condition>
  <arm_group>
    <arm_group_label>Intensive glycemic control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a target of blood glucose range of 130 mg/dL or less</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional glycemic control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a target of blood glucose range of 130-180 mg/dL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin for glycemic control according to the allocation</description>
    <arm_group_label>Conventional glycemic control</arm_group_label>
    <arm_group_label>Intensive glycemic control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age older than 18 years old.&#xD;
&#xD;
          -  History of type 2 diabetes mellitus for at least three months or a blood glucose level&#xD;
             of 200 mg per deciliter or higher in two different consecutive measurements.&#xD;
&#xD;
          -  A minimum of three days of hospitalization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetic ketoacidosis or hyperosmolar non-ketotic state at any stage of&#xD;
             hospitalization.&#xD;
&#xD;
          -  Patients expected to require intensive care unit admission or immediate surgical&#xD;
             intervention.&#xD;
&#xD;
          -  History of current drug or alcohol abuse.&#xD;
&#xD;
          -  History of current mental illness.&#xD;
&#xD;
          -  Child-bearing potential or a positive urine pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alon Grossman, Prof</last_name>
    <phone>+972-504065545</phone>
    <email>along@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irit Ayalon Dangur, Dr</last_name>
    <phone>+972-525940042</phone>
    <email>iritayalon1234@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mogher Khamaisi, Prof</last_name>
      <email>Khamaisi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alon Grossman, Prof</last_name>
      <phone>+972504065545</phone>
      <email>along@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Irit Ayalon Dangur, Dr</last_name>
      <phone>+972525940042</phone>
      <email>iritayalon1234@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>irit ayalon dangur</investigator_full_name>
    <investigator_title>Dr, Internal Medicine Doctor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>hyperglycemic control</keyword>
  <keyword>hospitalization</keyword>
  <keyword>internal medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

